TCGA-DK-A3IN-01A-11R-A20F-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 8.212877792
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.510
- MITOTIC_SPINDLE+0.390
- MYC_TARGETS_V2+0.390
- G2M_CHECKPOINT+0.360
- INFLAMMATORY_RESPONSE+0.360
- TGF_BETA_SIGNALING+0.340
- ANGIOGENESIS+0.330
- NOTCH_SIGNALING+0.330
- E2F_TARGETS+0.310
- ALLOGRAFT_REJECTION+0.280
Top 10 suppressed
- KRAS_SIGNALING_DN-0.280
- PANCREAS_BETA_CELLS-0.250
- OXIDATIVE_PHOSPHORYLATION-0.220
- CHOLESTEROL_HOMEOSTASIS-0.190
- PEROXISOME-0.190
- HEDGEHOG_SIGNALING-0.170
- P53_PATHWAY-0.170
- FATTY_ACID_METABOLISM-0.130
- MYOGENESIS-0.100
- INTERFERON_ALPHA_RESPONSE-0.080
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR10899983 | — | — | 0.853 |
| 2 | TCGA-FD-A3B7-01A-31R-A20F-07 | — | — | 0.815 |
| 3 | SRR934760 | — | — | 0.810 |
| 4 | TCGA-50-5933-01A-11R-1755-07 | — | cohortA1 | 0.808 |
| 5 | TCGA-DK-A3WX-01A-22R-A22U-07 | — | — | 0.798 |
| 6 | SRR934962 | — | — | 0.797 |
| 7 | TCGA-91-6848-01A-11R-1949-07 | — | cohortA1 | 0.797 |
| 8 | SRR934881 | — | — | 0.795 |
| 9 | SRR934813 | — | — | 0.793 |
| 10 | BS_NR3P3GN2 | high-grade glioma | — | 0.784 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.390 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.390 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.360 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.310 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.280 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.180 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.150 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |